Pet Pharm Biotech Co (ROCO:7762) Interest Expense : NT$-0.2 Mil (TTM As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Pet Pharm Biotech Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pet Pharm Biotech Co's interest expense for the six months ended in Jun. 2024 was NT$ -0.1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-0.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pet Pharm Biotech Co's Operating Income for the six months ended in Jun. 2024 was NT$ 1.5 Mil. Pet Pharm Biotech Co's Interest Expense for the six months ended in Jun. 2024 was NT$ -0.1 Mil. Pet Pharm Biotech Co's Interest Coverage for the quarter that ended in Jun. 2024 was 14.79. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pet Pharm Biotech Co Interest Expense Historical Data

The historical data trend for Pet Pharm Biotech Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pet Pharm Biotech Co Interest Expense Chart

Pet Pharm Biotech Co Annual Data

Trend

Dec22

Dec23

Interest Expense

-0.20

-0.18

Pet Pharm Biotech Co Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24
Interest Expense	-	-0.08	-0.10	-0.10

Pet Pharm Biotech Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-0.2 Mil.

Pet Pharm Biotech Co (ROCO:7762) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pet Pharm Biotech Co's Interest Expense for the six months ended in Jun. 2024 was NT$-0.1 Mil. Its Operating Income for the six months ended in Jun. 2024 was NT$1.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was NT$39.4 Mil.

Pet Pharm Biotech Co's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Jun. 2024 )	/	Interest Expense (Q: Jun. 2024 )
	=	-1	*	1.464	/	-0.099
	=	14.79

The higher the ratio, the stronger the company's financial strength is.

Pet Pharm Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pet Pharm Biotech Co Ltd (ROCO:7762) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051

Website

https://www.petpharmbio.com

Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.

Pet Pharm Biotech Co Headlines

No Headlines